The Japanese government on Friday conditionally approved the commercialization of two regenerative medicine products prepared from induced pluripotent stem cells, marking the world's first.The two iPS-derived drugs are ReHeart, developed by Cuorips Inc. to treat patients with severe heart failure stemming from ischemic cardiomyopathy, and Amchepry, produced by Sumitomo Pharma Co. and Racthera Inc. to treat Parkinson's disease, a progressive neurodegenerative disorder.With their prices and insurance application still needing further discussions, treatment using the drugs is expected to begin…READ FULL ARTICLE
